65,900 Shares in ADMA Biologics Inc $ADMA Acquired by Strs Ohio

Key Points

• Strs Ohio invested approximately $1.31 million in ADMA Biologics, purchasing 65,900 shares of the biotechnology company during the first quarter.
• ADMA Biologics reported a 13.8% increase in revenue year-over-year, achieving $121.98 million for the quarter, while beating the consensus earnings estimate by $0.01.
• The company's stock price has a one-year range of $13.50 to $25.67, indicating significant volatility and potential for growth.

Strs Ohio purchased a new stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 65,900 shares of the biotechnology company's stock, valued at approximately $1,307,000.

Other large investors have also made changes to their positions in the company. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of ADMA Biologics in the 1st quarter valued at approximately $35,000. SVB Wealth LLC bought a new stake in shares of ADMA Biologics in the 1st quarter valued at approximately $35,000. Smartleaf Asset Management LLC grew its stake in shares of ADMA Biologics by 161.4% in the 1st quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock valued at $49,000 after buying an additional 1,493 shares in the last quarter. Tsfg LLC bought a new stake in shares of ADMA Biologics in the 1st quarter valued at approximately $51,000. Finally, Brooklyn Investment Group grew its stake in shares of ADMA Biologics by 28,655.6% in the 1st quarter. Brooklyn Investment Group now owns 2,588 shares of the biotechnology company's stock valued at $51,000 after buying an additional 2,579 shares in the last quarter. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Down 1.5%

Shares of NASDAQ ADMA traded down $0.25 during trading hours on Friday, hitting $15.91. The stock had a trading volume of 8,438,957 shares, compared to its average volume of 3,313,825. The company has a market capitalization of $3.80 billion, a P/E ratio of 18.50 and a beta of 0.54. The firm's 50-day moving average price is $17.22 and its two-hundred day moving average price is $18.95. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The business had revenue of $121.98 million during the quarter, compared to analysts' expectations of $121.77 million. During the same quarter in the previous year, the business posted $0.13 EPS. The firm's quarterly revenue was up 13.8% compared to the same quarter last year. Analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.